Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2005

View Archived Issues

Buprenorphine attracts different patients with opioid dependence

Peginterferon alfa-2a reported more effective than lamivudine in hepatitis B

Adjuvant oral capecitabine therapy proven effective in colon cancer

Immunomodulators claimed in recent patents

New treatments for cancer reported in patent literature

Senju scientists synthesize novel calpain inhibitors

Garlic oil and allitridin improve glycemic control in diabetic rats

Bio-E-Gel reported to reduce hot flashes in menopausal women

Oblimersen plus rituximab shows efficacy in recurrent B-cell NHL

INS-316 improves sensitivity of lung cancer diagnosis with sputum specimens

Phase I data on the pharmacokinetics and safety of EKB-569 in advanced cancer patients

Pralatrexate shows promise in the treatment of advanced NSCLC

Prous Science to host Annual European Forum

Alfresa and AnGes collaborate on agent for atopic dermatitis in Japan

Lundbeck and PAION partner on desmoteplase

Enrollment completed in phase III trial of Infergen for HCV

MLN-1202 enters phase II study for relapsing-remitting MS

Final cohort begins dosing in phase II study of SABER-Bupivacaine

Phase IIb study evaluates BXL-628 for benign prostatic hyperplasia

AstraZeneca and Avanir establish reverse cholesterol transport collaboration

New River obtains license for technology to reduce opioid tolerance

VioQuest to acquire Greenwich Therapeutics

Arexis names fat malabsorption treatment Exinalda

Antares develops proprietary antianxiety transdermal gel

Canadian panel recommends return of Vioxx to market

U.S. antitrust approval for merger of Sankyo and Daiichi

Prous Science webcasts more than 100 hours of ADA 65th Scientific Session

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.